
==== Front
Adv TherAdv TherAdvances in Therapy0741-238X1865-8652Springer Healthcare Cheshire 31873867118510.1007/s12325-019-01185-0CorrectionCorrection to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine http://orcid.org/0000-0001-7830-0247Handelsman Yehuda yhandelsman@gmail.com 1Muskiet Marcel H. A. 2Meneilly Graydon S. 31 Metabolic Institute of America, 18372 Clark St. Suite 212, Tarzana, CA 91356 USA 2 grid.7177.60000000084992262Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers (Location VUMC), 1081 HV Amsterdam, The Netherlands 3 grid.17091.3e0000 0001 2288 9830Department of Medicine, The University of British Columbia, 2775 Laurel Street, Vancouver, BC V5Z1M9 Canada 23 12 2019 23 12 2019 2020 37 2 973 973 © The Author(s) 2019Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.issue-copyright-statement© Springer Healthcare Ltd., part of Springer Nature 2020
==== Body
Correction to: Adv Ther (2019) 36:3321–3339 10.1007/s12325-019-01126-x
On page 3331 of the original article, the word, “/LYXUMIA” has been removed from the section RATIONALE FOR COMBINATION THERAPY COMPRISING GLP-1 RAs AND BASAL INSULIN and the associated reference, numbered 100, has been corrected to: Xultophy® (insulin degludec/liraglutide) [summary of product characteristics]. Bagsvaerd, Denmark: Novo Nordisk A/S https://www.ema.europa.eu/en/documents/product-information/xultophy-epar-product-information_en.pdf. Accessed November 2019.

